Human pluripotent stem cells can differentiate into various cell types that can be applied to human-based in vitro toxicity assays. One major advantage is that the reprogramming of somatic cells to produce human induced pluripotent stem cells (hiPSCs) avoids the ethical and legislative issues related to the use of human embryonic stem cells (hESCs). HiPSCs can be expanded and efficiently differentiated into different types of neuronal and glial cells, serving as test systems for toxicity testing and, in particular, for the assessment of different pathways involved in neurotoxicity. This work describes a protocol for the differentiation of hiPSCs into mixed cultures of neuronal and glial cells. The signaling pathways that are regulated and/or activated by neuronal differentiation are defined. This information is critical to the application of the cell model to the new toxicity testing paradigm, in which chemicals are assessed based on their ability to perturb biological pathways. As a proof of concept, rotenone, an inhibitor of mitochondrial respiratory complex I, was used to assess the activation of the Nrf2 signaling pathway, a key regulator of the antioxidant-response-element-(ARE)-driven cellular defense mechanism against oxidative stress.
Introduction
The US National Research Council report 1 envisioned a new toxicity testing paradigm in which regulatory toxicity testing would be shifted from an approach relying on phenotypic changes observed in animals to an approach focusing on mechanistic in vitro assays using human cells. Pluripotent stem cell (PSC) derivatives may represent alternatives to cancer cell models, as the obtained cells may more closely resemble the physiological conditions of human tissues and provide more relevant tools to study chemical-induced adverse effects. The two major types of PSC cultures that are most promising for toxicity testing are human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), which are currently widely used in the areas of basic research and regenerative medicine 2, 3 . This expertise can now be harnessed for the development of a new class of toxicological in vitro tests aimed at identifying the perturbed physiological pathways involved with the development of adverse effects in vivo. However, test methods for regulatory safety assessments based on hESCs would be unlikely to be accepted by all EU Member States and by countries worldwide due to possible ethical concerns and diverse national legislative policies regulating the use of embryo-derived cells.
hiPSCs share characteristics similar to hESCs 4, 5 and hold great potential for in vitro methods, both for identifying therapeutic targets, as well as for safety assessments. In addition, hiPSC technology mitigates the constraints of a limited donor pool and the ethical concerns associated with embryo-derived cells. A major challenge for hiPSCs is the demonstration that these cells can reproducibly generate a significant range of toxicologically relevant cell derivatives, with characteristics and responses typical of human tissues. Predefined levels of the selected markers are generally used to characterize cell populations after the differentiation process and to provide insights into the stability of the differentiation process. (Upper part) IMR90-hiPSC colonies can be cut into fragments to form embryoid bodies (EBs). After 2 days in vitro (DIV), EBs can be plated onto laminin-or standard matrix-coated dishes and cultured in the presence of neuroepithelial induction (NRI) medium to generate neuroectodermal derivatives (rosettes, here stained for nestin (green) and β-IIItubulin (red)). Rosettes can be dissociated, collected, replated on laminin-or standard matrix-coated dishes, and further differentiated into mature neuronal (NF200, red) and glial (GFAP, green) cells in the presence of neuronal differentiation (ND) medium. (Lower part) rosette-derived NSCs (nestin, red) can be expanded in the presence of neural induction (NI) medium, cryopreserved, or further differentiated in the presence of ND medium to form mixed neuronal (NF200, green) and glial (GFAP, red) cultures. Please click here to view a larger version of this figure.
Rosette dissociation and neuronal differentiation (Days 8 → 28)
NOTE: This procedure requires good manual skills and precision. To avoid collecting mesodermal and endodermal cells, only ectoderm rosette-like structures should be dissociated and collected. 1. On Day 8, cut the rosette-like structures into fragments under a stereoscopic microscope at 10X magnification in sterile conditions. Use a 1 mL syringe with a 30G needle. Note that the rosettes tend to easily detach from the dish when touched with the needle. 2. Complete the detachment of the rosette fragments using a 200-µL pipette. 3. Transfer the dish under the laminar flow hood and collect the rosette fragments and their medium into a 15 mL conical tube using a 1, 2, or 5 mL pipette. Rinse the dish with 2 mL of NRI medium to recover all fragments. 4. Spin down the rosette fragments at 112 x g for 2 min. 5. Aspirate the supernatant. 6. Gently resuspend the pellet in 1 mL of 1x DPBS (without calcium and magnesium) and gently pipette the rosette fragments up and down using a 1,000-µL pipette to partially dissociate them. 7. Add 4 mL of complete NRI medium and count the cells using trypan blue and an automated cell counter (see the 13. Characterize the neuronal/glial cell derivatives, as described in step 5 (see Table 2 for general acceptance criteria).
HiPSC-derived Neural Stem Cell (NSC) Expansion and Differentiation into Mixed Neurons and Glia
NOTE: NSCs derived from rosette fragments can be expanded and maintained following the procedure described below (Figure 1, lower part) . This allows for incrementing the number of cells for differentiation and chemical testing. Remove the supernatant and gently resuspend the cells in 1 mL of complete NI medium using a 1,000-µL pipette. 10. Further dilute the cell suspension in 3 or 4 mL of complete NI medium and count the cells using trypan blue and an automated cell counter (note: dilute 20 µL of cell suspension in 20 µL of trypan blue; the viability after thawing should be ≥ 80%). 11. Plate the NSCs in a coated 60-mm Petri dish (or T25 flask) at a density of about 50,000 cells/cm 2 .
Characterization of hiPSC-derived Neuronal and Glial Cells
NOTE: Upon differentiation, neuronal and glial derivatives can be characterized using different techniques, such as the ones described in the following sections.
1. Quantitative real-time PCR (qPCR) analyses 10 1. Spin down hiPSC colony fragments, EBs, and/or NSCs at 130 x g for 3 min. 2. Resuspend the cell pellet in 100 µL of cold RNA lysis buffer provided in a suitable kit for RNA extraction. 3. Alternatively, collect neuronal/glial derivatives directly from the plates by aspirating the medium and adding cold RNA lysis buffer to the wells to collects the cells. 4. Isolate the RNA following the manufacturer's instruction. 5. Reverse-transcribe 500 ng of the total RNA using a suitable kit for RNA to cDNA retrotranscription. 6. Run qPCR reactions in duplicate using appropriate master mix and primer sets (see the 
Immunocytochemistry and high-content imaging (HCI)
6,11
1. Fix the hiPSC colonies, NSCs, and/or neuronal/glial derivatives with cold 4% paraformaldehyde for 15 min at room temperature. The flow cytometric analysis of live (not fixed), undifferentiated hiPSCs can be performed to assess the expression of PSC-specific markers, such as SSEA4 (see the Table of Materials) . Undifferentiated hiPSC colonies can be analyzed for alkaline phosphatase activity using commercially available BCIP/NBT kits, following the manufacturers' instructions (see the Table of Materials) . Additionally, reverse phase protein array (RPPA) assays and analyses may be performed, as described in Reference 12 (for a list of tested antibodies, see the Table of Materials) .
3. Electrophysiological measurements 13 1. Plate the dissociated rosette fragments (after 7 DIV) or NSCs derived from rosettes on coated multielectrode arrays (MEAs; see the Table of Materials) in complete ND medium (~1 x 10 5 cells/single-well MEA chip).
2. Differentiate the cells for 3 weeks in complete ND medium, refreshing the medium twice a week. 3. At the end of differentiation, seal the MEA chips with a semi-permeable membrane under a laminar flow hood to keep the cultures sterile for repeated measurements. 4. Replace one of the electrodes with one ground reference, allowing for recordings from the remaining electrodes. 5. Record the mean firing rate (MFR; number of spikes/min) using an MEA amplifier with the integrated temperature process control adjusted to 37 °C and 5% CO 2 . 6. Detect peaks from the MEA raw data using threshold limit of -4.7σ (σ represents the standard deviation of the basal noise). 7. Process the post-recording data with a suitable software.
Representative Results

Characterization of undifferentiated hiPSCs
To assess the phenotype of the hiPSCs, the analysis of colony/cell morphology, the determination of PSC-specific markers, and the examination of gene expression and alkaline phosphate activity should be performed. Undifferentiated hiPSCs should be round, with large nucleoli and without abundant cytoplasm. The majority of the colonies should be characterized by a flat and tightly-packed morphology, indicative of an undifferentiated phenotype (Figure 2A and Figure 2B) . Additionally, more than 80% of the colonies should be positive for alkaline phosphatase activity staining ( Figure 2C About 80% of the cells should be positive for classic pluripotency-related markers, such as Oct4, SSEA3, SSEA4, and Tra1-60 ( Figure 2D-H and 3%, respectively, as shown in Figure 2H ). These results should be reproducible over passages. 
Assessment of pluripotency via EB formation
HiPSCs are pluripotent, meaning that they express three germ layer-related genes under appropriate conditions. To assess hiPSC pluripotency, it is possible to apply a common approach based on spontaneous EB formation, which induces the formation of the three germ layers 14 . Analyses of germ layer-specific genes must indicate a time-dependent increase of endoderm (α-fetoprotein (AFP) and Cytokeratin 18 (KRT18)), ectoderm (Nestin, SRY-box 1 (Sox1), and paired box 6 (Pax6)), and mesoderm (natriuretic peptide A (NPPA) and Brachyury-T) -related gene expression ( Figure 3A and Figure 3B) ; see the Upon rosette dissociation and replating onto laminin-or standard matrix-coated dishes or plates in the presence of complete ND medium, cells start undergoing differentiation into mixed cultures of neurons and glia, progressively forming clusters of neuronal cell bodies connected by bundles of neurites ( Figure 4C and Figure 4D) . Similar results should be obtained when analyzing neuronal populations obtained by expanding rosette-derived NSCs and differentiating them into neurons and glia. NSCs expanded from rosettes should be nestin + ( Figure 4E , inset showing nestin + cells).
After 21 days of differentiation, the cells should be positive for β-III-tubulin; NF200; Tau; and MAP2, the late marker of dendrites ( Figure 4D , 4F, and Figure 4H ), with at least 10 -15% of the cells positive for the glial fibrillary acidic protein (GFAP), an astroglial marker ( Figure 4G and Figure  4H ). Moreover, ~20 -30% of the cells should retain the expression of nestin after differentiation ( Figure 4H) . It is important to consider that the percentage of each cell type (i.e., neuron, astrocyte, nestin + cells) may vary over passages, and user-dependent variability may be observed.
By analyzing specific neuronal subpopulations, GABAergic neurons represent ~15 -20% of the total cells, dopaminergic neurons ~13 -20%, and glutamatergic neurons ~35 -42%, as shown by immunostaining for gamma-aminobutyric acid (GABA), tyrosine hydroxylase (TH), and vesicular glutamate transporter 1 (VGlut1), respectively (see the representative quantification in Figure 4H ). The induction of differentiation can also be assessed by the analysis of pluripotency-related markers (e.g., Oct4, Tra1-60, and SSEA3), which should be significantly downregulated in differentiated cells versus undifferentiated hiPSCs (not shown, see Reference 6) . This can also be confirmed through the analysis of gene expression by qPCR, which should indicate a decrease of Oct4 and Nanog and the upregulation of neuronal genes, such as neural cell adhesion molecule 1 (NCAM1) and microtubule-associated protein 2 (MAP2); the presynaptic gene, synaptophysin (SYP); and the post-synaptic gene, microtubule-associated protein tau (MAPT), as shown in Figure 4I . Furthermore, dopaminergic (TH and NR4A1), noradrenergic (PHOX2A and PHOX2B), glutamatergic (NARG2, GRIA1 and GAP43), GABAergic (GABRA1 and GABRA3), motor neurons (ISL1 and LHX3), and cholinergic (SLC5A7 and SLC18A13) -related genes result in upregulated neuronal cells compared to undifferentiated cells ( Figure 4J ).
The analysis of spontaneous electrical activity, by means of MEA, is a valuable readout to assess the functionality of the neuronal network in differentiated hiPSCs. At the end of the differentiation period, neuronal derivatives are generally characterized by a mean firing rate (MFR) of at least 60 spikes/min (see the representative raster plot in Figure 4K ). However, bursts are not observed. 
A specific signature of neuronal markers is upregulated in differentiated IMR90-hiPSCs
In the new toxicity testing paradigm, it is essential to define the molecular and cellular events occurring within a cell following exposure to a given toxicant. Therefore, it is relevant to characterize which signaling pathways are activated and/or upregulated within the cellular model under investigation.
Commercially available arrays for the analyses of protein kinase gene expression can be used to compare undifferentiated hiPSCs versus differentiated cells. Differentiated IMR90-hiPSCs undergo the upregulation of genes involved in the control of neurotrophin receptors, axon guidance regulation, neurite outgrowth modulation, glial-derived neurotrophic factor (GDNF) receptors, bone morphogenetic protein (BMP)/TGFbeta pathway, and platelet-derived growth factor (PDGF) receptors ( Figure 5A and Figure 5B ).
IMR90-hiPSC-derived neuronal/glial cultures can be used to assess the effects of rotenone
Rotenone, an inhibitor of complex I of the mitochondrial respiratory chain, is known to cause oxidative stress by triggering the activation of the Nrf2 pathway. Under quiescent conditions, Nrf2 is anchored in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1), an Nrf2 repressor, which facilitates Nrf2 ubiquitination and proteolysis 15 . Upon the induction of oxidative stress, Nrf2 translocates into the nucleus and activates the expression of Nrf2-ARE target genes 16 . IMR90-hiPSC-derived neurons and glial cells can be used to assess the effects of rotenone on Nrf2 activation by exposing the cells to different concentrations of rotenone (e.g., 1, 10, and 100 nM) for 24 h. These concentrations were established according to previous studies 17, 18 .
At these concentrations and times of exposure, rotenone did not result in cytotoxicity, as shown by the quantification of live DAPI + cell nuclei ( Figure 6A ). Rotenone induced Nrf2 nuclear translocation, especially after exposing the cells to 100 nM rotenone ( Figure 6B and Figure 6E ). At the same concentration, a significant decrease in cytoplasmic Keap1 was observed (Figure 6C) , together with an increase in both NAD(P)H quinone oxidoreductase 1 (NQO1) and Sulfiredoxin 1 (SRXN1), two Nrf2-target enzymes 19, 20 ( Figure 6D ). Figure 7D) . Analogously, previous in vivo and in vitro studies have described a rotenone-dependent and selective dopaminergic neuronal cell death Statistical significance was assessed by one-way ANOVA with Dunnett's Multiple Comparison Test as a post-test (comparing all columns versus the control column) 24 or by two-tailed unpaired or paired t-test according to the type of analysis. All data represent the average of at least three biological replicates ± the standard error of the mean (S.E.M.). An asterisk over a bar indicates a significant difference with the control group. * p < 0.05, ** p < 0.01, *** p < 0.001. . Further immunocytochemical and gene expression analyses would help to better define the regional specificity of the differentiated cell derivatives.
The two most critical steps in the differentiation protocol described in this document are: (i) the cutting of hiPSC colonies into homogenous fragments (which is critical for the generation of EBs with homogenous sizes) and (ii) the cutting of neuroectodermal structures (rosettes) for NSC differentiation, which requires significant manual skill and precision to avoid collecting mesodermal and endodermal cells that may reduce the proportions of neurons and glial cells obtained upon differentiation.
It is crucial to characterize the phenotypes of the cells during expansion (as undifferentiated colonies or NSCs) and during all differentiation steps. In particular, the gene and protein expression profiles of the neuronal/glial cell derivatives should show upregulation and activation of neuron-related signaling pathways, whereas the expression of pluripotency markers should be decreased.
The generation of EBs and neuroectodermal derivatives (rosettes) can be manually challenging and prone to variability. For this reason, we developed a protocol for the expansion of rosette-derived NSCs and their further differentiation into neuronal/glial cells.
Possible limitations of this differentiation protocol are mainly (i) the relatively low percentage of differentiated glial derivatives and (ii) the lack of mature neuronal network functions (as shown by the lack of bursts). Moreover, specific subpopulations of astrocytes can function as primary progenitors or NSCs 35 . While nestin/GFAP double-positive cells were not observed in this differentiated cell culture (data not shown), it is hypothesized that the GFAP + cells in these mixed cultures are astrocytic progenitors and astrocytes. It is plausible that by extending the time of differentiation, the number of astrocytes may increase, and their morphology may become more mature, as already indicated by previous works from Zhang's group 36, 37 .
In the new toxicity testing paradigm, knowledge on chemical-induced perturbations of biological pathways is of the utmost importance when assessing chemical adversity. Therefore, in vitro test systems should be able to relate adverse effects to disturbances of signaling pathways, according to the concept of the adverse outcome pathway (AOP). As a proof-of-concept, rotenone can be used to assess the activation of the Nrf2 pathway, which is involved in the cellular defense against oxidative or electrophilic stress 38 , and oxidative stress is an important and common key event in various AOPs relevant to developmental and adult neurotoxicity 39 .
Rotenone should elicit the activation of the Nrf2 pathway, which can be demonstrated by Nrf2 protein nuclear translocation and increased expression of Nrf2-target enzymes, including NQO1 and SRXN1. It has been found that rotenone induces a dose-dependent increase of GFAP protein levels, indicative of astrocyte activation 40, 41 . Rotenone also decreases the number of dopaminergic (TH + ) cells, which is in agreement with previous in vitro and in vivo studies showing rotenone-dependent dopaminergic cell death, since this type of neuron is particularly sensitive to oxidative stress 21, 22, 23 .
In conclusion, this hiPSC-derived neuronal and glial cell culture model is a valuable tool to assess the neurotoxic effects of chemicals that elicit oxidative stress resulting in Nrf2 pathway activation. As this differentiation protocol allows for the generation of mixed cultures of neuronal cells (GABAergic, dopaminergic, and glutamatergic neurons) and astrocytes, it may prove suitable for studying the crosstalk between neurons and glia in physiological and pathological conditions, such as in neurodegenerative diseases (e.g., Parkinson's disease). Moreover, the presence of a significant proportion of NSCs may help to assess the possible effects of chemicals on neural progenitors, which are known to be the main target of chemically-induced mutations or viral infections 42 .
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